Background Molecular imaging of lung diseases, including asthma, is limited and either invasive or non-specific. Central to the inflammatory process in asthma is the recruitment of eosinophils to the airways, which release proteases and proinflammatory factors and contribute to airway remodeling. The aim of this study was to establish a new approach to non-invasively assess lung eosinophilia during the course of experimental asthma by combining non-invasive near-infrared fluorescence (NIRF) imaging with the specific detection of Siglec-F, a lectin found predominantly on eosinophils. Methodology/Principal Findings An ovalbumin (OVA)-based model was used to induce asthma-like experimental allergic airway disease (EAAD) in BALB/c mice. By means of a NIRF imager, we demonstrate that 48 h–72 h after intravenous (i.v.) application of a NIRF-labeled anti-Siglec-F antibody, mice with EAAD exhibited up to 2 times higher fluorescence intensities compared to lungs of control mice. Furthermore, average lung intensities of dexamethasone-treated as well as beta-escin-treated mice were 1.8 and 2 times lower than those of untreated, EAAD mice, respectively and correlated with the reduction of cell infiltration in the lung. Average fluorescence intensities measured in explanted lungs confirmed the in vivo findings of significantly higher values in inflamed lungs as compared to controls. Fluorescence microscopy of lung cryosections localized the i.v. applied NIRF-labeled anti-Siglec-F antibody predominantly to eosinophils in the peribronchial areas of EAAD lungs as opposed to control lungs. Conclusion/Significance We show that monitoring the occurrence of eosinophils, a prominent feature of allergic asthma, by means of a NIRF-labeled antibody directed against Siglec-F is a novel and powerful non-invasive optical imaging approach to assess EAAD and therapeutic response in mice over time.
References
[1]
National Asthma Education and Prevention Program (2007) Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 120: S94–138 doi:10.1016/j.jaci.2007.09.043.
[2]
Al-Hajjaj MS (2011) Difficult-to-treat asthma, is it really difficult? Ann Thorac Med 6: 1–2 doi:–10.4103/1817–1737.74268.
[3]
Kim HY, DeKruyff RH, Umetsu DT (2010) The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol 11: 577–584 doi:10.1038/ni.1892.
[4]
Bates JHT, Rincon M, Irvin CG (2009) Animal models of asthma. Am J Physiol Lung Cell Mol Physiol 297: L401–410 doi:10.1152/ajplung.00027.2009.
[5]
Blyth DI, Pedrick MS, Savage TJ, Hessel EM, Fattah D (1996) Lung inflammation and epithelial changes in a murine model of atopic asthma. Am J Respir Cell Mol Biol 14: 425–438. doi: 10.1165/ajrcmb.14.5.8624247
[6]
Jannasch K, Missbach-Guentner J, Alves F (2009) Using in vivo imaging for asthma. Drug Discovery Today: Disease Models 6: 129–135 doi:10.1016/j.ddmod.2009.12.003.
[7]
Napp J, Mathejczyk JE, Alves F (2011) Optical imaging in vivo with a focus on paediatric disease: technical progress, current preclinical and clinical applications and future perspectives. Pediatr Radiol 41: 161–175 doi:10.1007/s00247-010-1907-0.
[8]
Weissleder R, Ntziachristos V (2003) Shedding light onto live molecular targets. Nat Med 9: 123–128 doi:–10.1038/nm0103–123.
[9]
Cortez-Retamozo V, Swirski FK, Waterman P, Yuan H, Figueiredo JL, et al. (2008) Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammation. J Clin Invest 118: 4058–4066 doi:10.1172/JCI36335.
[10]
Korideck H, Peterson JD (2009) Noninvasive quantitative tomography of the therapeutic response to dexamethasone in ovalbumin-induced murine asthma. J Pharmacol Exp Ther 329: 882–889 doi:10.1124/jpet.108.147579.
[11]
Biffi S, Dal Monego S, Dullin C, Garrovo C, Bosnjak B, et al. (2013) Dendritic Polyglycerolsulfate Near Infrared Fluorescent (NIRF) Dye Conjugate for Non-Invasively Monitoring of Inflammation in an Allergic Asthma Mouse Model. PLoS ONE 8: e57150 doi:10.1371/journal.pone.0057150.
[12]
Bochner BS (2009) Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy 39: 317–324 doi:–10.1111/j.1365–2222.2008.03173.x.
[13]
Zhang M, Angata T, Cho JY, Miller M, Broide DH, et al. (2007) Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109: 4280–4287 doi:10.1182/blood-2006-08-039255.
[14]
Feng Y, Mao H (2012) Expression and preliminary functional analysis of Siglec-F on mouse macrophages. J Zhejiang Univ Sci B 13: 386–394 doi:10.1631/jzus.B1100218.
[15]
Finkelman FD, Wills-Karp M (2008) Usefulness and optimization of mouse models of allergic airway disease. Journal of Allergy and Clinical Immunology 121: 603–606 doi:10.1016/j.jaci.2008.01.008.
[16]
Dyer KD, Garcia-Crespo KE, Killoran KE, Rosenberg HF (2011) Antigen profiles for the quantitative assessment of eosinophils in mouse tissues by flow cytometry. J Immunol Methods 369: 91–97 doi:10.1016/j.jim.2011.04.009.
[17]
Dullin C, Zientkowska M, Napp J, Missbach-Guentner J, Krell H-W, et al. (2009) Semiautomatic landmark-based two-dimensional-three-dimensional image fusion in living mice: correlation of near-infrared fluorescence imaging of Cy5.5-labeled antibodies with flat-panel volume computed tomography. Mol Imaging 8: 2–14.
[18]
Hammer ？, Harper DAT (n.d.) i Ryan, PD (2001) PAST: Paleontological statistics software package for education and data analysis. Palaeontologia Electronica 4: 9.
[19]
Haller J, Hyde D, Deliolanis N, de Kleine R, Niedre M, et al. (2008) Visualization of pulmonary inflammation using noninvasive fluorescence molecular imaging. J Appl Physiol 104: 795–802 doi:10.1152/japplphysiol.00959.2007.
[20]
Song DJ, Cho JY, Lee SY, Miller M, Rosenthal P, et al. (2009) Anti-Siglec-F Antibody Reduces Allergen-Induced Eosinophilic Inflammation and Airway Remodeling. J Immunol 183: 5333–5341 doi:10.4049/jimmunol.0801421.
[21]
Ohkawara Y, Lei XF, St？mpfli MR, Marshall JS, Xing Z, et al. (1997) Cytokine and eosinophil responses in the lung, peripheral blood, and bone marrow compartments in a murine model of allergen-induced airways inflammation. Am J Respir Cell Mol Biol 16: 510–520. doi: 10.1165/ajrcmb.16.5.9160833
[22]
Mojtabavi N, Dekan G, Stingl G, Epstein MM (2002) Long-lived Th2 memory in experimental allergic asthma. J Immunol 169: 4788–4796. doi: 10.4049/jimmunol.169.9.4788
[23]
Zimmermann N, McBride ML, Yamada Y, Hudson SA, Jones C, et al. (2008) Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 63: 1156–1163 doi:–10.1111/j.1398–9995.2008.01709.x.
[24]
Farid SS, Mirshafiey A, Razavi A (2012) Siglec-8 and Siglec-F, the new therapeutic targets in asthma. Immunopharmacol Immunotoxicol 34: 721–726 doi:10.3109/08923973.2011.589453.
[25]
Rubinstein E, Cho JY, Rosenthal P, Chao J, Miller M, et al. (2011) Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 53: 409–416 doi:10.1097/MPG.0b013e3182182ff8.
[26]
Pappas K, Papaioannou AI, Kostikas K, Tzanakis N (2013) The role of macrophages in obstructive airways disease: chronic obstructive pulmonary disease and asthma. Cytokine 64: 613–625 doi:10.1016/j.cyto.2013.09.010.
[27]
Uller L, Persson CGA, Erjef？lt JS (2006) Resolution of airway disease: removal of inflammatory cells through apoptosis, egression or both? Trends Pharmacol Sci 27: 461–466 doi:10.1016/j.tips.2006.07.006.
[28]
Ochi H, Hirani WM, Yuan Q, Friend DS, Austen KF, et al. (1999) T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 190: 267–280. doi: 10.1084/jem.190.2.267
[29]
Sallusto F, Mackay CR, Lanzavecchia A (1997) Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277: 2005–2007. doi: 10.1126/science.277.5334.2005
[30]
Wegmann M (2011) Targeting Eosinophil Biology in Asthma Therapy. American Journal of Respiratory Cell and Molecular Biology 45: 667–674 doi:–10.1165/rcmb.2011–0013TR.
[31]
Ackerman SJ, Kephart GM, Habermann TM, Greipp PR, Gleich GJ (1983) Localization of eosinophil granule major basic protein in human basophils. J Exp Med 158: 946–961 doi:10.1084/jem.158.3.946.
[32]
Hilderbrand SA, Weissleder R (2010) Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol 14: 71–79 doi:10.1016/j.cbpa.2009.09.029.
[33]
Berlier JE, Rothe A, Buller G, Bradford J, Gray DR, et al. (2003) Quantitative Comparison of Long-wavelength Alexa Fluor Dyes to Cy Dyes: Fluorescence of the Dyes and Their Bioconjugates. J Histochem Cytochem 51: 1699–1712 doi:10.1177/002215540305101214.
[34]
Aysola R, de Lange EE, Castro M, Altes TA (2010) Demonstration of the heterogeneous distribution of asthma in the lungs using CT and hyperpolarized helium-3 MRI. J Magn Reson Imaging 32: 1379–1387 doi:10.1002/jmri.22388.
[35]
Druilhe A, Létuvé S, Pretolani M (2003) Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis 8: 481–495. doi: 10.1023/a:1025590308147
[36]
Lindner I, Meier C, Url A, Unger H, Grassauer A, et al. (2010) Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation. BMC Immunol 11: 24 doi:–––10.1186/1471–2172–11–24.
Mao H, Kano G, Hudson SA, Brummet M, Zimmermann N, et al. (2013) Mechanisms of Siglec-F-induced eosinophil apoptosis: a role for caspases but not for SHP-1, Src kinases, NADPH oxidase or reactive oxygen. PLoS ONE 8: e68143 doi:10.1371/journal.pone.0068143.
[39]
Fulkerson PC, Rothenberg ME (2013) Targeting Eosinophils in Allergy, Inflammation and Beyond. Nat Rev Drug Discov 12. Available: http://www.ncbi.nlm.nih.gov/pmc/articles？/PMC3822762/. Accessed 13 January 2014.
